On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of the clinical trial VISION which showed that patients had a high chance of responding to the drug with sustained duration.

Tepmetko gives patients whose cancers have the exon 14 skipping change in MET more options for treatment.
микрозаймы онлайн быстро
Click here to read the full press release.